315 related articles for article (PubMed ID: 29737220)
1. Emerging reverse transcriptase inhibitors for HIV-1 infection.
Rai MA; Pannek S; Fichtenbaum CJ
Expert Opin Emerg Drugs; 2018 Jun; 23(2):149-157. PubMed ID: 29737220
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment.
Wang Y; De Clercq E; Li G
Expert Opin Drug Metab Toxicol; 2019 Oct; 15(10):813-829. PubMed ID: 31556749
[No Abstract] [Full Text] [Related]
3. Current insights and molecular docking studies of HIV-1 reverse transcriptase inhibitors.
Singh AK; Kumar A; Arora S; Kumar R; Verma A; Khalilullah H; Jaremko M; Emwas AH; Kumar P
Chem Biol Drug Des; 2024 Jan; 103(1):e14372. PubMed ID: 37817296
[TBL] [Abstract][Full Text] [Related]
4. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
6. An introduction to nucleoside and nucleotide analogues.
Squires KE
Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
[TBL] [Abstract][Full Text] [Related]
7. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Balzarini J
Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
[TBL] [Abstract][Full Text] [Related]
8. Elsulfavirine: First Global Approval.
Al-Salama ZT
Drugs; 2017 Oct; 77(16):1811-1816. PubMed ID: 28940154
[TBL] [Abstract][Full Text] [Related]
9. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
Tabassum T; Azeem SM; Muwonge AN; Frey KM
Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
[TBL] [Abstract][Full Text] [Related]
10. Investigational reverse transcriptase inhibitors for the treatment of HIV.
Cory TJ; Midde NM; Rao P; Kumar S
Expert Opin Investig Drugs; 2015; 24(9):1219-28. PubMed ID: 26088266
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
Boyle A; Moss CE; Marzolini C; Khoo S
Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
[TBL] [Abstract][Full Text] [Related]
12. Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations.
Sörstedt E; Carlander C; Flamholc L; Hejdeman B; Svedhem V; Sönnerborg A; Gisslén M; Yilmaz A
Int J Antimicrob Agents; 2018 May; 51(5):733-738. PubMed ID: 29371105
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
[TBL] [Abstract][Full Text] [Related]
14. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection.
Wonganan P; Limpanasithikul W; Jianmongkol S; Kerr SJ; Ruxrungtham K
Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):551-564. PubMed ID: 32508203
[TBL] [Abstract][Full Text] [Related]
16. Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.
Moyo S; Gaseitsiwe S; Zahralban-Steele M; Maruapula D; Nkhisang T; Mokaleng B; Mohammed T; Ditlhako TR; Bareng OT; Mokgethi TP; van Widenfelt E; Pretorius-Holme M; Mine MO; Raizes E; Yankinda EK; Wirth KE; Gaolathe T; Makhema JM; Lockman S; Essex M; Novitsky V
AIDS; 2019 May; 33(6):1073-1082. PubMed ID: 30946161
[TBL] [Abstract][Full Text] [Related]
17. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
J Antimicrob Chemother; 2023 Aug; 78(8):1921-1928. PubMed ID: 37303226
[TBL] [Abstract][Full Text] [Related]
18. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of the interaction when switching non-nucleoside reverse transcriptase inhibitors in patients infected with HIV.
Dailly E; Allavena C; Deslandes G; Bouquie R; Jolliet P; Raffi F
Curr Clin Pharmacol; 2014; 9(4):399-403. PubMed ID: 24218996
[TBL] [Abstract][Full Text] [Related]
20. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
La Regina G; Coluccia A; Silvestri R
Antivir Chem Chemother; 2010 Aug; 20(6):213-37. PubMed ID: 20710063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
